SG10201809696UA - Processes and intermediates for preparing a medicament - Google Patents

Processes and intermediates for preparing a medicament

Info

Publication number
SG10201809696UA
SG10201809696UA SG10201809696UA SG10201809696UA SG10201809696UA SG 10201809696U A SG10201809696U A SG 10201809696UA SG 10201809696U A SG10201809696U A SG 10201809696UA SG 10201809696U A SG10201809696U A SG 10201809696UA SG 10201809696U A SG10201809696U A SG 10201809696UA
Authority
SG
Singapore
Prior art keywords
intermediates
processes
medicament
preparing
2a
Prior art date
Application number
SG10201809696UA
Inventor
Philip Pye
Haim Cyril Ben
Matteo Conza
Ioannis Nicolaos Houpis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361786842P priority Critical
Priority to EP13159470 priority
Priority to EP13197813 priority
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG10201809696UA publication Critical patent/SG10201809696UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT 5 Disclosed is a process for the preparation of the following compounds: NH2 N N O N R 1 NC NH2 N N R 2a N R 1 R 1a where R 1, R1a and R 2a have the definitions in the description, as well as a process to 10 prepare other intermediates that may be useful to synthesise downstream products, especially compounds that are useful as medicaments, for instance Bruton’s tyrosine kinase (Btk) inhibitors such as ibrutinib. Also disclosed are other processes, other intermediates and compounds per se . 15 [No available fig.]
SG10201809696UA 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament SG10201809696UA (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201361786842P true 2013-03-15 2013-03-15
EP13159470 2013-03-15
EP13197813 2013-12-17

Publications (1)

Publication Number Publication Date
SG10201809696UA true SG10201809696UA (en) 2018-11-29

Family

ID=51535892

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201809696UA SG10201809696UA (en) 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament
SG11201507595XA SG11201507595XA (en) 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201507595XA SG11201507595XA (en) 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament

Country Status (12)

Country Link
EP (1) EP2970291A1 (en)
JP (1) JP2016510779A (en)
KR (1) KR20150132172A (en)
CN (1) CN105026400A (en)
AU (2) AU2014230935A1 (en)
BR (1) BR112015021856A2 (en)
CA (1) CA2901510A1 (en)
EA (1) EA201591685A1 (en)
MX (1) MX2015012731A (en)
PE (1) PE16522015A1 (en)
SG (2) SG10201809696UA (en)
WO (1) WO2014139970A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105884747A (en) * 2014-08-28 2016-08-24 北京赛林泰医药技术有限公司 Preparation method for preparing Bruton's tyrosine kinase (BTK) inhibitor
CN104447761A (en) * 2014-11-27 2015-03-25 广东东阳光药业有限公司 Method for preparing pyrazole derivative
WO2016115869A1 (en) * 2015-01-21 2016-07-28 中国科学院合肥物质科学研究院 Novel inhibitor of flt3 kinase and use thereof
CN105481862B (en) * 2015-01-21 2018-08-21 中国科学院合肥物质科学研究院 Flt3 kinase novel inhibitors and their use
LV15201B (en) 2015-08-31 2017-07-20 Latvijas Organiskās Sintēzes Institūts The method for the preparation of ibrutinib intermediate
CN106608877B (en) * 2015-10-21 2018-11-13 新发药业有限公司 Lu by one kind of imatinib intermediate 4-amino-3- (4-aminophenoxy) phenyl -1H- pyrazolo [3,4-d] pyrimidine Preparation
WO2018103058A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018145280A1 (en) * 2017-02-09 2018-08-16 合肥合源药业有限公司 Flt3 kinase inhibitor or crystal forms of salt thereof and preparation method therefor
CN107383017A (en) * 2017-07-20 2017-11-24 河南师范大学 High-efficiency preparation method for ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1212327T3 (en) * 1999-09-17 2003-12-15 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
PL2530083T3 (en) 2006-09-22 2016-11-30 Inhibitors of bruton's tyrosine kinase
EP2543375A1 (en) * 2007-03-28 2013-01-09 Pharmacyclics, Inc. Pyrrolo-pyrimidine analogues as inhibitors of bruton's tyrosine kinase
EP2089391B1 (en) * 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
US8623879B2 (en) * 2008-04-02 2014-01-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivates and their use as PDE9A modulators
KR20120003868A (en) 2009-03-31 2012-01-11 베링거 인겔하임 인터내셔날 게엠베하 1-heterocyclyl-1,5-dyhydro-pyrazolo[3,4-d]pyrimidine-4-one derivatives and their use as pde9a modulators
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CA2804648C (en) * 2010-07-09 2019-01-22 The Walter And Eliza Hall Institute Of Medical Research Protein kinase inhibitors and methods of treatment
WO2012058645A1 (en) * 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
AU2012283775A1 (en) * 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
GEP201706748B (en) * 2012-08-10 2017-10-10 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
CA2888960C (en) * 2012-11-02 2017-08-15 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (en) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 Bruton's tyrosine kinases inhibitor

Also Published As

Publication number Publication date
KR20150132172A (en) 2015-11-25
PE16522015A1 (en) 2015-11-12
JP2016510779A (en) 2016-04-11
EA201591685A1 (en) 2016-01-29
AU2018204086A1 (en) 2018-06-28
MX2015012731A (en) 2016-02-18
SG11201507595XA (en) 2015-10-29
CA2901510A1 (en) 2014-09-18
WO2014139970A1 (en) 2014-09-18
CN105026400A (en) 2015-11-04
AU2014230935A1 (en) 2015-09-03
EP2970291A1 (en) 2016-01-20
BR112015021856A2 (en) 2017-07-18

Similar Documents

Publication Publication Date Title
MX2014007024A (en) Antibodies against human csf-1r and uses thereof.
MX2012013324A (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof.
MX2014000747A (en) Btk inhibitors.
IL227399D0 (en) New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
MX2014005928A (en) Heterocyclic inhibitors of glutaminase.
MX2012009862A (en) Bisaryl-bonded aryltriazolones and use thereof.
IL227678D0 (en) C-17 and c-3 modified triterpenoids wiht hiv maturation inhibitory activity
CU20140131A7 (en) Benzamide derivatives for the inhibition of the activity of ABL1, ABL2 and bcr-ABL1
SG194219A1 (en) Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
SI2763982T1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX348470B (en) Substituted annellated pyrimidine and the use thereof.
MX2008010416A (en) Process for the preparation of optically active chiral amines.
MX355409B (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-inda zol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylam ino)-benzamide.
MX2013008850A (en) Compositions and methods for treating cardiovascular diseases.
IL227987D0 (en) Compounds and compositions as trk inhibitors
TW201247674A (en) Pyrrolotriazinone derivatives as PI3K inhibitors
SG182713A1 (en) Pyrazole derivatives as jak inhibitors
PH12015501385A1 (en) Autotaxin inhibitors
MX2014000029A (en) Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators.
TW201441234A (en) BTK inhibitors
TW201412750A (en) Inhibitors of human immunodeficiency virus replication
IL228677D0 (en) Branched 3-phenylpropionic acid derivatives and the use thereof
TW201408662A (en) Dihydropyrimidine compounds and their application in pharmaceuticals